GlassScriptPhysician profile
Daniel H Miller
NPI 1447694922
$5,746.74
in general payments reported to CMS, 2019-2025
54 companies · $1,701 in 2025
The $1,701 reported for 2025 was more than what 89% of Radiation Oncology providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $250 · 2020: $133 · 2021: $670 · 2022: $941 · 2023: $805 · 2024: $1,247 · 2025: $1,701.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,619 · Education: $134.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,618.50 |
| Education | $134.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $730.38 | 2021-2025 | Enhertu, Datroway |
| Astrazeneca Pharmaceuticals LP | $438.80 | 2020-2025 | Enhertu, Lynparza, Calquence |
| Merck Sharp & Dohme LLC | $279.38 | 2024-2025 | Keytruda, Keytruda Qlex, Lynparza |
| Janssen Biotech, INC. | $274.05 | 2021-2025 | Erleada, Darzalex, Akeega |
| Bayer Healthcare Pharmaceuticals INC. | $252.58 | 2022-2025 | |
| Genentech USA, INC. | $227.62 | 2021-2025 | Tecentriq, Perjeta, Kadcyla |
| Regeneron Healthcare Solutions, INC. | $212.65 | 2022-2024 | Libtayo |
| Incyte Corporation | $187.67 | 2021-2025 | Jakafi, Monjuvi |
| Eisai INC. | $181.63 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $168.97 | 2021-2025 | |
| Sumitomo Pharma America, INC. | $154.76 | 2023-2025 | Orgovyx |
| E.R. Squibb & Sons, L.L.C. | $153.71 | 2020-2025 | Opdivo |
| Novocure INC. | $144.35 | 2019-2024 | Optune |
| Lilly USA, LLC | $137.60 | 2022-2025 | Verzenio, Jaypirca |
| Integra Lifesciences Corporation | $134.68 | 2019 |
Show all 54 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $132.78 | 2021-2025 | |
| Seagen INC. | $131.58 | 2022-2025 | Adcetris |
| Amgen INC. | $124.02 | 2020-2023 | Lumakras, Vectibix, Nplate |
| Medtronic, INC. | $121.83 | 2022-2025 | Synchromedii, Osteocool Rf Ablation System |
| Takeda Pharmaceuticals U.S.A., INC. | $121.29 | 2021-2025 | Fruzaqla, Ninlaro |
| Glaxosmithkline, LLC. | $116.54 | 2021-2024 | Zejula, Jemperli |
| Boehringer Ingelheim Pharmaceuticals, INC. | $109.71 | 2022-2023 | Gilotrif |
| Tersera Therapeutics LLC | $106.48 | 2021-2025 | Zoladex |
| Jazz Pharmaceuticals INC. | $103.57 | 2021-2025 | |
| Genzyme Corporation | $99.75 | 2021-2023 | |
| Emd Serono, INC. | $81.09 | 2021-2025 | |
| Pfizer INC. | $67.51 | 2021-2024 | |
| Icotec Medical INC. | $59.02 | 2024 | Icotec Blackarmor Spine System |
| Sobi, INC | $54.32 | 2024-2025 | |
| Foundation Medicine, INC. | $52.58 | 2020-2023 | |
| Ipsen Biopharmaceuticals, INC | $43.22 | 2021-2023 | Tazverik |
| Varian Medical Systems, INC. | $38.25 | 2019 | |
| Syndax Pharmaceuticals, INC. | $37.87 | 2025 | Revuforj |
| Apellis Pharmaceuticals, INC. | $32.22 | 2023-2024 | Empaveli |
| Legend Biotech USA INC. | $31.64 | 2025 | Carvykti |
| Servier Pharmaceuticals LLC | $31.56 | 2022 | |
| Rigel Pharmaceuticals, INC. | $27.13 | 2025 | Tavalisse, Gavreto, Rezlidhia |
| Janssen Pharmaceuticals, INC | $26.93 | 2021-2022 | |
| Myriad Genetic Laboratories, INC. | $26.69 | 2024 | Myrisk |
| Iovance Biotherapeutics, INC. | $24.20 | 2025 | Amtagvi |
| Exelixis INC. | $24.15 | 2024 | Cabometyx |
| Gilead Sciences, INC. | $22.65 | 2022 | |
| Biocompatibles, INC. | $21.82 | 2019 | |
| Geron Corporation | $21.66 | 2025 | Rytelo |
| Astellas Pharma US INC | $21.30 | 2021 | |
| Teleflex LLC | $21.08 | 2025 | Barrigel |
| Alexion Pharmaceuticals, INC. | $20.65 | 2021 | |
| Deciphera Pharmaceuticals INC. | $20.57 | 2025 | Qinlock, Romvimza |
| Cycle Pharmaceuticals INC | $16.99 | 2025 | Phyrago |
| Morphosys, US INC. | $16.23 | 2022 | |
| Karyopharm Therapeutics INC. | $15.91 | 2024 | Xpovio |
| G1 Therapeutics, INC. | $15.78 | 2022 | |
| Genmab U.S., INC. | $14.10 | 2025 | Epkinly |
| Aveo Pharmaceuticals, INC. | $13.24 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.